Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
- PMID: 18064037
- DOI: 10.1038/nm1698
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
Abstract
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
Comment in
-
Broadly neutralizing antibodies against hepatitis C virus: new hope for immunization?Gastroenterology. 2008 Jun;134(7):2184-6. doi: 10.1053/j.gastro.2008.05.020. Epub 2008 May 13. Gastroenterology. 2008. PMID: 18482587 No abstract available.
-
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs.J Hepatol. 2008 Aug;49(2):299-300. doi: 10.1016/j.jhep.2008.05.008. Epub 2008 May 23. J Hepatol. 2008. PMID: 18554744
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
